Microdosing PMX to achieve maximum synergistic activity with PDE biochemical inhibition, at a dose 10,000 lower than that which is clinically utilized, may present its own challenges considering that sublethal dosing of cytotoxic chemotherapy can promote the acquisition of drug resistance in lung cancer cells in vitro [61,62]. The gene discussed is ALDH7A1; the disease is lung carcinoma.